June 01, 2011 08:52 ET

Equity Research on Immucor Inc. and Celldex Therapeutics Inc. - Diagnostic Substances Sector Sees Volumes and Prices Improve

NEW YORK, NY--(Marketwire - Jun 1, 2011) - has a handpicked team of market professionals with over 100 years of combined investing experience. Today they are providing members comprehensive research on the Diagnostic Substances industry and are offering free analytical research on Immucor Inc. (NASDAQ: BLUD) and Celldex Therapeutics Inc. (NASDAQ: CLDX). Register with us today at to have free access to this research or speak to one of our pros at

The Diagnostic Substances sector has seen improvement among its volumes and pricing lately as the overall health care landscape strengthens. Patients who are now less apt to postpone medical care for financial reasons are beginning to utilize health care services more often. This has been good for results for some companies within the sector. Get instant analyses of Immucor Inc. and Celldex Therapeutics Inc. from live, real-time experts standing by at There is no commitment to join. is the Ultimate Trading Environment for investors. If you are considering owning Immucor Inc. and Celldex Therapeutics Inc. then you should sign up for a free membership and our complimentary reports today at Over the last 5 years our returns outpaced any of the major indexes. Sign up today to find out what you are missing.

Immucor Inc., for example, which has benefited from the pricing and volume increases, was upgraded this month by RBC. Immucor Inc. report is accessible for free by registering today at

The biotech sector has been strong overall and several companies have become attractive targets for acquisition by larger companies. Those with strong moats or a lot of pipeline potential offer larger companies with the capital to acquire them great opportunities to boost their revenues. Celldex Therapeutics Inc. report is accessible for free by registering today at

Celldex Therapeutic Inc. which has been losing money recently due to declining revenue could be one of these valuable targets thanks to major cancer treatments that could be on the way.

The two Diagnostic Substances stocks research reports are available for free by signing up now on


Shine's Room Online is the brain child of David Shine, a 15 year Wall Street veteran with a stellar track record. For 13 years Shine has trained thousands of traders to navigate and profit from the markets. Using cutting edge technology, Shine provides you with a community in which you can trade alongside Shine and his Team as they guide you through the market's ever-changing landscape.

To view our disclaimer, visit this link

Contact Information